{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 95,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Uses a timeline framework to show the progression of negligence.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/37",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-37",
  "components": [
    {
      "bbox": null,
      "kind": "framework",
      "text": "Timeline of MM-110 program failures",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecacb92d-324d-4e95-8b8c-e24c99d315a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.5,
        "y": 0.6
      },
      "kind": "list",
      "text": "Jan 2022: Phase I completed with patients dosed at 660mg (35x higher than FDA-allowed limit without safety studies).",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ae1df8e-07e2-4305-b571-1700284a65b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "2015: FDA required preclinical safety trials; allowed low doses pending completion. Mice were dying at 20mg.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68cbfb82-1dce-4ef3-b592-48794a18e336",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "list",
      "text": "April 2020: Dr. Freeman started low-dose (<20mg) Phase I trial and left MindMed while dosing was at 8mg.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7910be7c-6f77-4b93-a46f-2a16e8978e31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "Jan 2021 - June 2021: Trial amended to allow dosing upwards of 1,200mg.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a07e618b-9652-4b9e-9b6c-9a8da74bc30e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Company SEDAR Filings, Company SEC Filings, MindMed Press Releases, Clinicaltrials.gov. See [3]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28811f59-fc62-452b-aff5-57d3a2034b4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Categorical Failure of MM-110 Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92665068-7325-4815-90cb-17d03d9d4d28",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "5c5e3825-6680-4017-8cb1-1d181ee6d3d9",
      "evidence": "Chronological presentation of events",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 60,
      "from": 15,
      "beatId": "46c295b3-1c69-4f4e-b465-df8201aa88d9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problems by highlighting the company's lack of accountability, excessive executive compensation, and dilutive financing approach.",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}